🔎 Trials Near Me

Home › Acute Myeloid Leukemia › District of Columbia › Washington

Pag-aaral pangklinika para sa Acute Myeloid Leukemia sa Washington, DC

24 pag-aaral para sa Acute Myeloid Leukemia ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Washington (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

Nagha-hire para sa pag-aaral dito? I-highlight ito sa tuktok ng pahinang ito — $99 sa loob ng 30 araw →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Nagre-recruitPhase 2
  • Walter Reed National Military Medical Center, Bethesda · 7 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT05564390

Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

Nagre-recruitPhase 1
  • National Institutes of Health Clinical Center, Bethesda · 7 mi ang layo
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Okt 5, 2026 · NCT06904066

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
  • MedStar Georgetown University Hospital, Washington D.C.
  • MedStar Washington Hospital Center, Washington D.C.
  • Walter Reed National Military Medical Center, Bethesda · 7 mi ang layo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Nagre-recruitPhase 2
  • Walter Reed National Military Medical Center, Bethesda · 7 mi ang layo
Edad 18 hanggang 59 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Nagre-recruitPhase 3
  • Center for Cancer and Blood Disorders, Bethesda · 7 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06852222

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Nagre-recruitPhase 2
  • Walter Reed National Military Medical Center, Bethesda · 7 mi ang layo
Edad 18 hanggang 59 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Nagre-recruitPhase 2
  • Walter Reed National Military Medical Center, Bethesda · 7 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Set 22, 2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Nagre-recruitPhase 3
  • MedStar Georgetown University Hospital, Washington D.C.
  • Children's National Medical Center, Washington D.C.
  • Walter Reed National Military Medical Center, Bethesda · 7 mi ang layo
6 Months – 21 Years · Lahat ng kasarian · Na-update Set 17, 2026 · NCT04293562

Longitudinal Studies of Patient With FPDMM

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
  • National Institutes of Health Clinical Center, Bethesda · 7 mi ang layo
1 Day – 100 Years · Lahat ng kasarian · Na-update Set 11, 2026 · NCT03854318

The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation

Nagre-recruitPhase 1/2Malugod na tinatanggap ang malusog na boluntaryo
  • National Institutes of Health Clinical Center, Bethesda · 7 mi ang layo
Edad 12 hanggang 120 · Lahat ng kasarian · Na-update Set 11, 2026 · NCT05436418

A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies

Nagre-recruitObservasyonal na pag-aaral
  • The Center for Cancer and Blood Disorders, Bethesda · 7 mi ang layo
Edad 0 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT07154823

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Nagre-recruitPhase 3
  • Children's National - Main Hospital, Washington D.C.
29 Days – 21 Years · Lahat ng kasarian · Na-update Ago 24, 2026 · NCT05183035

Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...

Nagre-recruitPhase 1
  • National Institutes of Health Clinical Center, Bethesda · 7 mi ang layo
Edad 3 hanggang 35 · Lahat ng kasarian · Na-update Ago 24, 2026 · NCT02390752

Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies

Nagre-recruitPhase 1
  • Childrens National Medical Center, Washington D.C.
6 Months – 80 Years · Lahat ng kasarian · Na-update Ago 14, 2026 · NCT02203903

Comprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
  • National Institutes of Health Clinical Center, Bethesda · 7 mi ang layo
1 Day – 120 Years · Lahat ng kasarian · Na-update Hul 23, 2026 · NCT05350748

Collection of Blood, Bone Marrow, Skin, Saliva, and Stool Samples From Healthy Volunteers Used for Comparative Analysis of Myeloid Malignancies

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
  • National Institutes of Health Clinical Center, Bethesda · 7 mi ang layo
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Hul 23, 2026 · NCT05588154

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Nagre-recruitObservasyonal na pag-aaral
  • Children's National Medical Center, Washington D.C.
  • Nih/Niaid, Bethesda · 7 mi ang layo
  • Nih/Nhlbi, Bethesda · 7 mi ang layo
Lahat ng edad · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT01351545

Study of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants

Nagre-recruitObservasyonal na pag-aaral
  • National Institutes of Health Clinical Center, Bethesda · 7 mi ang layo
1 Month – 120 Years · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT07019155

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Nagre-recruitPhase 1/2
  • The Center for Cancer and Blood Disorders (CCBD), Bethesda · 7 mi ang layo
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 24, 2026 · NCT04068597

Cancer Experience Registry (CER) for Cancer Patients and Caregivers

Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
  • Cancer Support Community Research & Training Institute, Washington D.C.
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 23, 2026 · NCT02333604

Massage Impact on Sleep in Pediatric Oncology

Nagre-recruit
  • Children's National Hospital, Washington D.C.
Edad 12 hanggang 21 · Lahat ng kasarian · Na-update Abr 15, 2026 · NCT06892158

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Nagre-recruitPhase 1/2
  • Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
Edad 12 pataas · Lahat ng kasarian · Na-update Mar 24, 2026 · NCT04988555

Phase IB/II of CPX-351 for Relapse Prevention in AML

Nagre-recruitPhase 1/2
  • Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 23, 2026 · NCT04990102

Pag-aaral para sa Acute Myeloid Leukemia sa ibang lungsod

Iba pang pag-aaral sa Washington

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.